Ocular Therapeutix (OCUL) Cash from Operations (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Cash from Operations of 67272000.0 for Q2 2026, down 21.79% year-over-year from 86009877.23 in Q2 2025, and down 1.94% on a QoQ basis from 65993000.0 in Q1 2026.
Ocular Therapeutix (OCUL) Cash from Operations (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Cash from Operations for 14 years, with the latest figure at 67272000.0 in Q2 2026.
- Cash from Operations for Q2 2026 came in at 67272000.0, down 21.79% year-over-year; the trailing twelve-month figure through Jun 2026 was 238239000.0 (down 35.44% YoY), and the FY2025 annual result was 204883000.0, down 52.13% from the prior year.
- Cash from Operations fell to 67272000.0 in Q2 2026, from 65993000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 7732000.0 in Q3 2023 and troughed at 67272000.0 in Q2 2026.
- A 5-year average of 33481222.22 and a median of 29344500.0 in 2024 frame the typical range for Cash from Operations.
- The widest annual swing landed in 2022, when Cash from Operations soared 45.77%; it then tumbled 372.83% in 2024.
- A 5-year view of Cash from Operations shows it stood at 16958000.0 in 2022, then sank by 32.41% to 22454000.0 in 2023, then sank by 75.6% to 39429000.0 in 2024, then slumped by 37.59% to 54249000.0 in 2025, then dropped by 24.01% to 67272000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Operations figures were 67272000.0 in Q2 2026, 65993000.0 in Q1 2026, and 54249000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -67.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.27 Mn |
| Jun 30, 2026 | -67.27 Mn |
| Mar 31, 2026 | -65.99 Mn |
| Mar 31, 2026 | -65.99 Mn |
| Dec 31, 2025 | -54.25 Mn |
| Dec 31, 2025 | -54.25 Mn |
| Sep 30, 2025 | -50.73 Mn |
| Sep 30, 2025 | -50.73 Mn |
| Jun 30, 2025 | -55.24 Mn |
| Jun 30, 2025 | -55.24 Mn |
| Mar 31, 2025 | -44.67 Mn |
| Mar 31, 2025 | -44.67 Mn |
| Dec 31, 2024 | -39.43 Mn |
| Dec 31, 2024 | -39.43 Mn |
| Sep 30, 2024 | -36.56 Mn |
| Sep 30, 2024 | -36.56 Mn |
| Jun 30, 2024 | -24.80 Mn |
| Jun 30, 2024 | -24.80 Mn |
| Mar 31, 2024 | -33.89 Mn |
| Mar 31, 2024 | -33.89 Mn |